3-AMINOBENZAMIDE, A POLY (ADP-RIBOSE) POLYMERASE INHIBITOR, RESTORES BIOENERGETICS BUT FAILS TO ALLEVIATE EXCITOTOXICITY AND MOTOR FUNCTIONS IN 3-NITROPROPIONIC ACID INTOXICATED MICE
Objective: The present study was undertaken to investigate the effects of 3-aminobenzamide (3-AB), a poly (ADP-ribose) polymerase 1 (PARP1) inhibitor, on motor functions along with brain excito toxicity and bioenergetics alterations in 3-nitropropionic acid (3-NPA) intoxicated mice model of Huntingtonâ€™s disease (HD).
Methods: Young healthy male C57BL/6J mice were pre-treated with vehicle/3-AB for a period of five days and intoxicated with two doses of 3-NPA (15 mg/kg, i. p) at 24 h interval on day 4 and 5. Animals were observed for motor functions 5 days after 3-NPA injection. They were sacrificed at the end of motor tests and brains were collected for neurochemical, bioenergetics, glial cells and cytokines analysis.
Results: 3-AB treatment significantly increased the bioenergetics (ATP and NAD) and succinate dehydrogenase activity in 3-NPA intoxicated mice brains. But, it failed to decrease glutamate content, cytokines-TNFÎ± and IL-1Î² and glial markersâ€“glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 (IBA1) expressions. Further, 3-AB administered produced only a non-significant restoration of motor functions in 3-NPA intoxicated mice.
Conclusion: The present study revealed that excito toxicity and inflammatory pathways are major perpetrators in 3-NPA induced neuro degeneration and motor dysfunction. Therapeutic approach with 3-AB alone may not be sufficient to manage the multi-cascade pathogenetic mechanisms in HD neither symptomatic management too.
2. Rangone H, Humbert S, Saudou F. Huntingtonâ€™s disease: How does huntingtin, an antiapoptotic protein, become toxic? Pathol Biol 2004;52:338â€“42.
3. Estrada-Sanchez AM, Mejia-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntingtonâ€™s disease. Arch Med Res 2008;39:265â€“76.
4. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005;95:1521â€“40.
5. Kumar P, Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntingtonâ€™s disease like symptoms: Possible behavioural, biochemical and cellular alterations. Eur J Pharmacol 2009;615:91â€“101.
6. TÃºnez I, Santamaria A. Model of Huntingtonâ€™s disease induced with 3-nitropropionic acid. Rev Neurol 2009;48:430â€“4.
7. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999;18:4446â€“54.
8. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 2003;85:306â€“17.
9. Ullrich O, Diestel A, Eyupoglu IY, Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 2001;3:1035â€“42.
10. Koh S, Chang D, Kim H, Kim J, Kim M, Kim KS, et al. Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology 2005;214:131â€“9.
11. Strosznajder R, Gajkowskar B. Effect of 3-aminobenzamide on Bcl-2, Bax and AIF localization in hippocampal neurons altered by ischemia-reperfusion injury. The histochemical study. Acta Neurobiol Exp 2006;66:15-22.
12. Nam E, Lee YJ, Oh YA, Jung JA, Im HI, Koh SE, et al. Involvement of oxidative stress and Poly(ADP-ribose) polymerase activation in 3-nitropropionic acid-induced cytotoxicity in human neuroblastoma cells. Korean J Physiol Pharmacol 2003;7:325-31.
13. Babu CS, Ramanathan M. Pre-ischemic treatment with memantine reversed the neurochemical and behavioural parameters but not energy metabolites in middle cerebral artery occluded rats. Pharmacol Biochem Behav 2009;92:424â€“32.
14. Kalaivani P, Ganesh M, Gayathiri V, Jyothi Priya R, Pramila B, Sunil AG, et al. Alterations in SIRT1 and PARP1 expression precedes oxidative stress event in rats subjected to transient focal cerebral ischemia: Molecular and Histopathological evidences. J Stroke Cerebrovascular Dis 2014;23:2753-66.
15. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M. 3-Nitropropinic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991;18:492â€“8.
16. Tunez I, Tasset I, La Cruz VP, Santamaria A. 3-Nitropropionic acid as a tool to study the mechanisms involved in huntingtonâ€™s disease: past, Present and future. Molecules 2010;15:878-16.
17. Schallert T. Behavioural tests for preclinical intervention assessment. Neurotherapeutics 2006;3:497-504.
18. Kim ST, Son HJ, Choi JH, Ji IJ, Hwang O. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinsonâ€™s disease. Brain Res 2010;1306:176-83.
19. Babu CS, Sunil AG, Hannah RV, Muthusamy VS, Ramanathan M. Development and validation of an HPTLC method for simultaneousestimation of excitatory neurotransmitters in rat brain. J Liq Chromatogr Relat Technol 2007;30:2891â€“902.
20. Bregman AA. Laboratory Investigations In Cell Biology, viii, Wiley, New York: Chichester; 1987. p. 268.
21. Zhan C, Yang J. Protective effects of isoliquiritigenin in transient middle cerebral artery occlusion-induced focal cerebral ischemia in rats. Pharmacol Res 2006;53:303-9.
22. Bradford MM. A rapid and sensitive method for the quantitation ofmicrogram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248â€“54.
23. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntingtonâ€™s disease. Physiol Rev 2010;90:905â€“81.
24. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003;112:481â€“90.
25. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Sci 2004;305:626â€“9.
26. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41:646â€“53.
27. Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell 2006;17:1652â€“63.
28. Wullner U, Young AB, Penney JB, Beal MF. 3-Nitropropionic acid toxicity in the striatum. J Neurochem 1994;63:1772-81.
29. Ranju V, Sathiya S, Kalaivani P, Priya RJ, Babu CS. Memantine exerts functional recovery by improving BDNF and GDNF expression in 3-nitropropionic acid intoxicated mice. Neurosci Let 2015;586:1â€“7.
30. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-D-aspartate receptor rmediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002;33:849-60.
31. Schiefer J, Sprunken A, Puls C, Luesse HG, Milkereit A, Milkereit E, et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 2004;1019:246-54.
32. Lo EH, Bosque-Hamilton P, Meng W. Inhibition of Poly(ADP-Ribose) polymerase: reduction of ischemic injury and attenuation of N-Methyl-d-Aspartateâ€“Induced neurotransmitter dysregulation. Stroke 1998;29:830-6.
33. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005;171:1001â€“12.
34. Jang M, Lee MJ, Kim CS, Cho I. Korean red ginseng extract attenuates 3-nitropropionic acid-induced huntingtonâ€™s-like symptoms. Evidence-Based Complementary Altern Med 2013;2013:1-17.